-6-K As previously reported on a Form 6-K filed by BeyondSpring Inc. (the “Company”), Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”), the Company’s 58%-owned subsidiary in China,
June 14, 9:07 AM
Gainers Blue Water Biotech (NASDAQ:BWV) stock moved upwards by 115.2% to $1.7 during Wednesday’s pre-market session. The market…
May 2, 8:00 AM
Credit Suisse boosted the price target for KBR, Inc. (NYSE: KBR) from $68 to $71. Credit Suisse analyst Jamie Cook maintained an Outperform rating. KBR shares rose 4.4% to close at $59.16 on Monday.
BeyondSpring Provides Business Update And Reports Year End 2022 Financial Results; As Of December 31, 2022, The Company Had Cash, Cash Equivalents, And Short-Term Investments Of $37.3M
April 18, 4:41 PM
- SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration - BeyondSpring Completed Enrollment of Three Investigator-Initiated Trials (IIT) with Plinabulin in the
February 10, 2:07 PM
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development Agreement with the U.S. Department of Justice's Federal Bureau of Investigation.
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday’s Mid-Day Session
December 21, 2:51 PM
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday’s Mid-Day Session
December 16, 2:47 PM
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.
December 16, 1:31 PM
Gainers Allarity Therapeutics (NASDAQ:ALLR) stock rose 164.2% to $0.7 during Friday’s regular session. As of 12:30 EST, this…
December 13, 1:14 PM
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
BeyondSpring Presents Data With Plinabulin For The Prevention Of Docetaxel-Induced Neutropenia In Patients With Non-Small Cell Lung Cancer And Breast Cancer At Three Medical Conferences
December 13, 9:08 AM
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxel In an